Skip Ribbon Commands
Skip to main content
Sign In
Navigate Up

24877 ADAMTS13 Evaluation (1295)

ADAMTS13 Evaluation (1295)
Test Code: ADAMTSO
Synonyms/Keywords
ADAMTS Activity and Inhibitor, VWF Cleaving Protease
Test Components
ADAMTS13 Evaluation is a reflexive testing algorithm. The activity testing is always performed, with reflex testing of the inhibitor assay and antibody assay performed if indicated by the activity test results.
Useful For
​Diagnosing Thrombotic Thrombocytopenic Purpura  (TTP)
Specimen Requirements
Specimen Type Preferred Container/Tube Acceptable Container/Tube Specimen Volume Specimen Minimum Volume
(allows for 1 repeat)		 Pediatric Minimum Volume
(no repeat)
Plasma​ ​Citrated Blue Top Tube (BTT) ​ ​Three 0.5 mL aliquots ​Two 0.4 ml aliquots ​
OR​ ​ ​ ​ ​ ​
​Serum ​Red Top Tube ​ ​Three 0.5 mL aliquots ​Two 0.4 ml aliquots ​
Collection Processing Instructions

Ship sample frozen.​

Specimen Stability Information
Specimen Type Temperature Time
​Plasma or Serum ​ ​ ​ ​Ambient ​7 days
​Refrigerated ​7 days
​Frozen -20 deg C ​2 weeks
​Frozen -80 deg C ​6 months
Rejection Criteria
Samples collected in EDTA are not acceptable.
Performing Laboratory Information
Performing Location Day(s) Test Performed Analytical Time Methodology/Instrumentation
Blood Center of Wisconsin​ Monday through Friday​
Activity and Inhibitor: 2-4 days
Antibody: 7-10 days

FRET based kinetic assay​

Reference Lab
Versiti/Blood Center of Wisconsin
Test Information
​ADAMTS13 Activity is always performed. If activity is < or = 30%, the inhibitor will be performed at an additional charge. If the inhibitor is < 0.7, the ADAMTS13 Antibody will be performed at an additional charge. ADAMTS13 is a plasma protein that regulates the interaction of platelets with von Willebrand factor. Absent or low ADAMTS13 activity allows formation of platelet microthrombi, which in turn obstruct arterioles and capillaries, generating the clinical sequelae of Thrombotic thrombocytopenic purpura (TTP). ADAMTS13 deficiency can be congenital or acquired. In idiopathic TTP, acquired deficiency of ADAMTS13 is attributed to the presence of autoantibody, which may either inhibit ADAMTS13 function (which is reported as an inhibitor) or may cause clearance of circulation ADAMTS13. While patients with congenital deficiency of ADAMTS13 respond to simple plasma infusion therapy, patients with idiopathic TTP usually require therapeutic plasma exchange to achieve clinical remission.
The rapid ADAMTS13 test (Testcode ADAMT13) is recommended when the diagnosis of thrombotic thrombocytopenia purpura (TTP) is being considered and therapeutic decisions hang in the balance (e.g. placement of a central line and initiation of plasma exchange). Same day turn-around-time (TAT) is necessary and the rapid ADAMTS13 in-house assay performed by Marshfield Laboratories is appropriate.
For follow-up of a patient with TTP to assess recurrence risk, a more delayed TAT is acceptable, and the less expensive sendout ADAMTS13 test (Testcode ADAMTSO) is appropriate.
Consultation with a hematologist, hematopathologist, or coagulation specialist is advised for unusual clinical situations.
Reference Range Information
Performing Location Reference Range
​Blood Center of Wisconsin
ADAMTS Activity: > or = 67%
ADAMTS Inhibitor: < or = 0.4 Inhibitor Units​
Outreach CPTs
CPT Modifier
(if needed)		 Quantity Description Comments
​85397 ​ ​1 ADAMTS13 Activity​ ​
​85335 ​ ​1 ADAMTS13 Inhibitor (if performed)​ ​
​83520 ​ ​1 ADAMTS13 Antibody (if performed)​ ​
Synonyms/Keywords
ADAMTS Activity and Inhibitor, VWF Cleaving Protease
Test Components
ADAMTS13 Evaluation is a reflexive testing algorithm. The activity testing is always performed, with reflex testing of the inhibitor assay and antibody assay performed if indicated by the activity test results.
Ordering Applications
Ordering Application Description
​Centricity ​ADAMTS13 Evaluation (1295)
​Cerner ​ADAMTS13 Evaluation (1295)
​COM ​ADAMTS13 Evaluation
If the ordering application you are looking for is not listed, contact your local laboratory for assistance.
Specimen Requirements
Specimen Type Preferred Container/Tube Acceptable Container/Tube Specimen Volume Specimen Minimum Volume
(allows for 1 repeat)		 Pediatric Minimum Volume
(no repeat)
Plasma​ ​Citrated Blue Top Tube (BTT) ​ ​Three 0.5 mL aliquots ​Two 0.4 ml aliquots ​
OR​ ​ ​ ​ ​ ​
​Serum ​Red Top Tube ​ ​Three 0.5 mL aliquots ​Two 0.4 ml aliquots ​
Collection Processing

Ship sample frozen.​

Specimen Stability Information
Specimen Type Temperature Time
​Plasma or Serum ​ ​ ​ ​Ambient ​7 days
​Refrigerated ​7 days
​Frozen -20 deg C ​2 weeks
​Frozen -80 deg C ​6 months
Rejection Criteria
Samples collected in EDTA are not acceptable.
Useful For
​Diagnosing Thrombotic Thrombocytopenic Purpura  (TTP)
Test Components
ADAMTS13 Evaluation is a reflexive testing algorithm. The activity testing is always performed, with reflex testing of the inhibitor assay and antibody assay performed if indicated by the activity test results.
Reference Range Information
Performing Location Reference Range
​Blood Center of Wisconsin
ADAMTS Activity: > or = 67%
ADAMTS Inhibitor: < or = 0.4 Inhibitor Units​
For more information visit:
Performing Laboratory Information
Performing Location Day(s) Test Performed Analytical Time Methodology/Instrumentation
Blood Center of Wisconsin​ Monday through Friday​
Activity and Inhibitor: 2-4 days
Antibody: 7-10 days

FRET based kinetic assay​

Reference Lab
Versiti/Blood Center of Wisconsin
For billing questions, see Contacts
Outreach CPTs
CPT Modifier
(if needed)		 Quantity Description Comments
​85397 ​ ​1 ADAMTS13 Activity​ ​
​85335 ​ ​1 ADAMTS13 Inhibitor (if performed)​ ​
​83520 ​ ​1 ADAMTS13 Antibody (if performed)​ ​
For most current information refer to the Marshfield Laboratory online reference manual.